Key points are not available for this paper at this time.
This study shows that specifically blocking PD-1 immunosuppression can potently enhance CAR T-cell therapy that has significant implications for potentially improving therapeutic outcomes of this approach in patients with cancer.
John et al. (Sat,) studied this question.